Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity

Journal of Psychiatric Research

Volumn 46, Issue 6, 2012, Pages 819-824

  Pedrini, Mariana ^a,b   Massuda, Raffael ^a,b   Fries, Gabriel R ^a,b   de Bittencourt Pasquali, Matheus A ^b   Schnorr, Carlos Eduardo ^b   Moreira, José Claudio F ^b   Teixeira, Antonio L ^c   Lobato, Maria Ines R ^a,b   Walz, Julio C ^a   Belmonte de Abreu, Paulo Silva ^a,b   Kauer Sant'Anna, Marcia ^a,b   Kapczinski, Flavio ^a,b   Gama, Clarissa S ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Inflammatory cytokines; Oxidative stress; Schizophrenia; Staging

Indexed keywords

ANTIOXIDANT; CARBONYL DERIVATIVE; INTERLEUKIN 10; INTERLEUKIN 6; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD SAMPLING; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OVERT SCHIZOPHRENIA; OXIDATIVE STRESS; PRIORITY JOURNAL; SCHIZOPHRENIA; TOTAL REACTIVE ANTIOXIDANT POTENTIAL; VEIN PUNCTURE;

ADULT; AGE OF ONSET; CHRONIC DISEASE; CYTOKINES; FEMALE; HUMANS; MALE; MEDIATOR COMPLEX; MIDDLE AGED; PROTEIN CARBONYLATION; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC; THIOBARBITURIC ACID REACTIVE SUBSTANCES; YOUNG ADULT;

EID: 84861221372     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.03.019     Document Type: Article

References (50)

1. Agius M., Goh C., Ulhaq S., McGorry P. The staging model in schizophrenia, and its clinical implications. Psychiatria Danubina 2010, 22(2):211-220.
2. Arvindakshan M., Sitasawad S., Debsikdar V., Ghate M., Evans D., Horrobin D.F., et al. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biological Psychiatry 2003, 53(1):56-64.
3. Berk M., Hallam K.T., McGorry P.D. The potential utility of a staging model as a course specifier: a bipolar disorder perspective. Journal of Affective Disorders 2007, 100(3):279-281.
4. Berk M., Malhi G.S., Hallam K., Gama C.S., Dodd S., Andreazza A.C., et al. Early intervention in bipolar disorders: clinical, biochemical and neuroimaging imperatives. Journal of Affective Disorders 2009, 114(1-3):1-13.
5. Berk M., Conus P., Kapczinski F., Andreazza A.C., Yücel M., Wood S.J., et al. From neuroprogression to neuroprotection: implications for clinical care. Medical Journal of Australia 2010, 193(4 Suppl.):S36-S40. PubMed PMID: 20712560.
6. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neuroscience Biobehavior Review 2011, 35(3):804-817.
7. Cazzullo C.L., Sacchetti E., Galluzzo A., Panariello A., Colombo F., Zagliani A. Cytokine profiles in drug-naive schizophrenic patients. Schizophrenia Research 2001, 47(2-3):293-298.
8. Dean B. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. International Journal of Neuropsychopharmacology 2011, 14(7):997-1012. Epub 2010 Dec 15. Review. PubMed PMID: 21156092.
9. Drexhage R.C., Hoogenboezem T.A., Cohen D., Versnel M.A., Nolen W.A., van Beveren N.J., et al. An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces. International Journal of Neuropsychopharmacology 2011, 14(6):746-755.
10. Dietrich-Muszalska A., Olas B., Głowacki R., Bald E. Oxidative/nitrative modifications of plasma proteins and thiols from patients with schizophrenia. Neuropsychobiology 2009, 59(1):1-7.
11. Dietrich-Muszalska A., Olas B. Modifications of blood platelet proteins of patients with schizophrenia. Platelets 2009, 20(2):90-96.
12. Dietrich-Muszalska A., Kontek B. Lipid peroxidation in patients with schizophrenia. Psychiatry and Clinical Neurosciences 2010, 64(5):469-475.
13. Dresch M.T., Rossato S.B., Kappel V.D., Biegelmeyer R., Hoff M.L., Mayorga P., et al. Optimization and validation of an alternative method to evaluate total reactive antioxidant potential. Analytical Biochemistry 2009, 385(1):107-114.
14. Francesconi L.P., Ceresér K.M., Mascarenhas R., Stertz L., Gama C.S., Belmonte-de-Abreu P. Increased annexin-V and decreased TNF-alpha serum levels in chronic-medicated patients with schizophrenia. Neuroscience Letters 2011, 502(3):143-146.
15. Francey S.M., Nelson B., Thompson A., Parker A.G., Kerr M., Macneil C., et al. Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. Schizophrenia Research 2010, 119(1-3):1-10.
16. Gama C.S., Salvador M., Andreazza A.C., Kapczinski F., Belmonte-de-Abreu P.S. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2006, 30(3):512-515.
17. Gama C.S., Andreazza A.C., Kunz M., Berk M., Belmonte-de-Abreu P.S., Kapczinski F. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neuroscience Letters 2007, 420(1):45-48.
18. Gama C.S., Berk M., Andreazza A.C., Kapczinski F., Belmonte-de-Abreu P. Serum levels of brain-derived neurotrophic factor and thiobarbituric acid reactive substances in chronically medicated schizophrenic patients: a positive correlation. Revista Brasileira de Psiquiatria 2008, 30(4):337-340.
19. Gama C.S., Salvador M., Andreazza A.C., Lobato M.I., Berk M., Kapczinski F., et al. Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males. Neuroscience Letters 2008, 433(3):270-273.
20. Grignon S., Chianetta J.M. Assessment of malondialdehyde levels in schizophrenia: a meta-analysis and some methodological considerations. Progress in Neuropsychopharmacology Biological Psychiatry 2007, 31(2):365-369.
21. Huang T.L., Liou C.W., Lin T.K. Serum thiobarbituric acid-reactive substances and free thiol levels in schizophrenia patients: effects of antipsychotic drugs. Psychiatry Research 2010, 177(1-2):18-21.
22. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophrenia Research 2002, 58(1):1-10.
23. Kapczinski F., Dias V.V., Kauer-Sant'Anna M., Brietzke E., Vázquez G.H., Vieta E., et al. The potential use of biomarkers as an adjunctive tool for staging bipolardisorder. Progress in Neuropsychopharmacology an Biological Psychiatry 2009, 33(8):1366-1371.
24. Kapczinski F., Dias V.V., Kauer-Sant'Anna M., Frey B.N., Grassi-Oliveira R., Colom F., et al. Clinical implications of a staging model for bipolar disorders. Expert Review of Neurotherapeutics 2009, 9(7):957-966.
25. Kapczinski F., Dal-Pizzol F., Teixeira A.L., Magalhaes P.V., Kauer-Sant'Anna M., Klamt F., et al. A systemic toxicity index developed to assess peripheral changes in mood episodes. Molecular Psychiatry 2010, 15(8):784-786.
26. Kapczinski F., Dal-Pizzol F., Teixeira A.L., Magalhaes P.V., Kauer-Sant'Anna M., Klamt F., et al. Peripheral biomarkers and illness activity in bipolar disorder. Journal of Psychiatric Research 2011, 45(2):156-161.
27. Kauer-Sant'Anna M., Kapczinski F., Andreazza A.C., Bond D.J., Lam R.W., Young L.T., et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. International Journal of Neuropsychopharmacology 2008, 12(4):447-458.
28. Kaur T., Cadenhead K.S. Treatment implications of the schizophrenia prodrome. Current Topics in Behavioral Neurosciences 2010, 4:97-121.
29. Kunz M., Gama C.S., Andreazza A.C., Salvador M., Ceresér K.M., Gomes F.A., et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 2008, 32(7):1677-1681.
30. Kunz M., Ceresér K.M., Goi P.D., Fries G.R., Teixeira A.L., Fernandes B.S., et al. Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Revista Brasileira de Psiquiatria 2011, 33(3):268-274.
31. Levine R.L., Garland D., Oliver C.N., Amici A., Climent I., Lenz A.G., et al. Determination of carbonyl content in oxidatively modified proteins. Methods in Enzymology 1990, 186:464-478.
32. Lieberman J.A. Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia. Journal of Clinical Psychiatry 1999, 60(Suppl. 12):9-12.
33. McGorry P.D., Nelson B., Goldstone S., Yung A.R. Clinical staging: a heuristic and practical strategy for new research and better health and social outcomes for psychotic and related mood disorders. Canadian Journal of Psychiatry 2010 Aug, 55(8):486-497.
34. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biological Psychiatry 2011, 70(7):663-671.
35. Mondelli V., Cattaneo A., Murri M.B., Di Forti M., Handley R., Hepgul N., et al. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. Journal of Clinical Psychiatry 2011, 72(12):1677-1684. Epub 2011 May 18.
36. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biological Psychiatry 2008, 63(8):801-808.
37. Reddy R.D., Yao J.K. Free radical pathology in schizophrenia: a review. Prostaglandins, Leukotrienes and Essential Fatty Acids 1996, 45:43-49.
38. Reinares M., Colom F., Rosa A.R., Bonnín C.M., Franco C., Solé B., et al. The impact of staging bipolar disorder on treatment outcome of family psychoeducation. Journal of Affective Disorders 2010, 123(1-3):81-86.
39. Riegel R.E., Valvassori S.S., Moretti M., Ferreira C.L., Steckert A.V., de Souza B., et al. Intracerebroventricular ouabain administration induces oxidative stress in the rat brain. International Journal of Developmental Neuroscience 2010, 28(3):233-237.
40. Romano F., Elkis H. Tradução e Adaptação de um Instrumento de Avaliação Psicopatológica das Psicoses: Escala Breve de Avaliação Psiquiátrica. Versão Ancorada (BPRS-A). Jornal Brasileiro de Psiquiatria 1996, 45:43-49.
41. Sasayama D., Wakabayashi C., Hori H., Teraishi T., Hattori K., Ota M., et al. Association of plasma IL-6 and soluble IL-6 receptor levels with the Asp358Ala polymorphism of the IL-6 receptor gene in schizophrenic patients. Journal of Psychiatric Research 2011, 45(11):1439-1444.
42. Scott J., Paykel E., Morriss R., Bentall R., Kinderman P., Johnson T., et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. British Journal of Psychiatry 2006, 188:313-320.
43. Sponheim S.R., Jung R.E., Seidman L.J., Mesholam-Gately R.I., Manoach D.S., O'Leary D.S., et al. Cognitive deficits in recent-onset and chronic schizophrenia. Journal of Psychiatric Research 2010, 44(7):421-428.
44. Strakowski S.M., DelBello M.P., Zimmerman M.E., Getz G.E., Mills N.P., Ret J., et al. Ventricular and periventricular structural volumes in first- versus multiple-episode bipolar disorder. American Journal of Psychiatry 2002, 159(11):1841-1847.
45. Velakoulis D., Wood S.J., Wong M.T., McGorry P.D., Yung A., Phillips L., et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Archives of General Psychiatry 2006, 63(2):139-149.
46. Vieta E., Reinares M., Rosa A.R. Staging bipolar disorder. Neurotoxicity Research 2011, 19(2):279-285.
47. Zhang M., Zhao Z., He L., Wan C. A meta-analysis of oxidative stress markers in schizophrenia. Science China Life Sciences 2010, 53(1):112-124.
48. Wayner D.D., Burton G.W., Ingold K.U., Locke S. Quantitative measurement of the total, peroxyl radical-trapping antioxidant capability of human blood plasma by controlled peroxidation. The important contribution made by plasma proteins. FEBS Letters 1985, 187(1):33-37.
49. Wills E.D. Mechanisms of lipid peroxide formation in animal tissues. Biochemical Journal 1966, 99:667-676.
50. Wood S.J., Yung A.R., McGorry P.D., Pantelis C. Neuroimaging and treatment evidence for clinical staging in psychotic disorders: from the at-risk mental state to chronic schizophrenia. Biological Psychiatry 2011, 70(7):619-625.